Download PDF
Thromb Haemost 1998; 79(05): 1029-1033
DOI: 10.1055/s-0037-1615115
Review Article
Schattauer GmbH

The Effects of Sex Steroids on Plasma Levels of Marker Proteins of Endothelial Cell Functioning

P. J. M. van Kesteren
1   From the Departments of Andrology, Amsterdam
,
T. Kooistra
4   From the Departments of Gaubius Laboratory, TNO-PG, Leiden, The Netherlands
,
M. Lansink
4   From the Departments of Gaubius Laboratory, TNO-PG, Leiden, The Netherlands
,
G. J. van Kamp
2   From the Departments of Clinical Chemistry, Amsterdam
,
H. Asscheman
1   From the Departments of Andrology, Amsterdam
,
L. J. G. Gooren
1   From the Departments of Andrology, Amsterdam
,
J. J. Emeis
4   From the Departments of Gaubius Laboratory, TNO-PG, Leiden, The Netherlands
,
U. M. Vischer
5   From the Department of Internal Medicine, Hôpital Cantonal et Universitaire de Genève, Geneva, Switzerland
,
C. D. A. Stehouwer
3   From the Departments of Internal Medicine, Academic Hospital Vrije Universiteit, Amsterdam
› Author Affiliations
Further Information

Publication History

Received 29 September 1997

Accepted after resubmission 14 January 1998

Publication Date:
07 December 2017 (online)

    Permissions and Reprints

Summary

We studied thirteen male-to-female (M→F) and ten female-to-male (F→M) transsexuals who, for four months, received cross-sex treatment with, respectively, ethinylestradiol and cyproterone acetate, and with testosterone esters. We assessed the effects of treatment on plasma levels of tissue-type plasminogen activator (tPA), von Willebrand factor (vWF), vWF-propeptide (vWF:AgII) and bigendothelin-1 (big-ET-1), four proteins that are markers of endothelial cell functioning. We also measured urokinase-type PA (uPA) and plasminogen activator inhibitor-type 1 (PAI-1), which may not be endothelium-derived but share major clearance pathways with tPA.

In M→F transsexuals, mean plasma levels of tPA (minus 4.4 ng/ml), big-ET-1 (minus 0.8 pg/ml), uPA (minus 0.5 ng/ml) and PAI-1 (minus 26 ng/ml) decreased (all Ps ≤0.02). The level of vWF increased (plus 24%; P = 0.005), while vWF:AgII did not change (P = 0.49).

In F→M transsexuals, levels of big-ET-1 increased (plus 0.4 pg/ml; P = 0.02), while tPA, uPA and PAI-1 did not change (all Ps >0.25). In this group vWF decreased (minus 14%; P = 0.06), but vWF:AgII did not change (P = 0.38).

Estrogens and androgens have clear effects on plasma levels of endothelial marker proteins. The mechanisms behind these effects are complex and appear to involve both altered secretion (big-ET-1) and processing and/or clearance (vWF and possibly tPA). Therefore, effects of hormones on the levels of endothelial marker proteins do not necessarily reflect changes in endothelial cell functioning, at least with regard to changes in vWF level associated with the oral administration of high doses of ethinylestradiol and cyproterone acetate to healthy men and the parenteral administration of testosterone to healthy women.

 

  • References

  • 1 Gangar KF, Reid BA, Crook D, Hillard TC, Whitehead MI. Oestrogens and atherosclerotic vascular disease – local vascular factors. Ballières Clin Endocrinol Metab 1993; 7: 47-59.
    PubMedGoogle Scholar
  • 2 Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-8.
    CrossrefPubMedGoogle Scholar
  • 3 Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
    CrossrefPubMedGoogle Scholar
  • 4 Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-5.
    CrossrefPubMedGoogle Scholar
  • 5 Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993; 88: 2030-4.
    CrossrefPubMedGoogle Scholar
  • 6 Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-9.
    CrossrefPubMedGoogle Scholar
  • 7 Kooistra T, Lansink M, van Kesteren P, Koolwijk P, Toet K, Peters E, Hegeman R, Emeis JJ, Stehouwer C, Gooren L, van Hinsbergh VWM. Effects of steroid hormones on the secretion of haemostatic factors in, and angiogenic properties of, human vascular endothelial cells. Gynecol Endocrinol 1996; 10 (Suppl. 02) 105-10.
    PubMedGoogle Scholar
  • 8 Kluft C, Verheijen JH. Leiden fibrinolysis working party: blood collection and handling procedures for assessment of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI-1). Fibrinolysis 1990; 4 (Suppl. 02) 155-61.
    PubMedGoogle Scholar
  • 9 Ingerslev J. A sensitive elisa for von Willebrand factor (vWF:Ag). Scand J Clin Lab Invest 1987; 47: 143-9.
    CrossrefPubMedGoogle Scholar
  • 10 Borchiellini A, Fijnvandraat K, ten Cate JW, Pajkrt D, van Deventer SJH, Pasterkamp G, Meyer-Huizinga F, Zwart-Huinink L, Voorberg J, van Mourik JA. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-argi-nine vasopressin in humans. Blood 1996; 88: 2951-8.
    PubMedGoogle Scholar
  • 11 Vischer UM, Ingerslev J, Wollheim CB, Mestries J-C, Tsakiris DA, Haefeli WE, Kruithof EKO. Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWF:AgII) levels. Thromb Haemost 1997; 77: 387-93.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Bos R, Hoegee-de Nobel E, Laterveer R, Meijer P, Nieuwenhuizen W. A one-step enzyme immunoassay for the determination of total tissue-type plasminogen activator (t-PA) antigen in plasma. Blood Coag Fibrinol 1992; 2: 303-7.
    PubMedGoogle Scholar
  • 13 Nieuwenhuizen W, Laterveer R, Hoegee-de Nobel E, Bos R. A one-step enzyme immunoassay for total plasminogen activator inhibitor-1 antigen in human plasma. Blood Coag Fibrinol 1995; 6: 268-72.
    CrossrefPubMedGoogle Scholar
  • 14 Koolwijk P, van Erck MGM, de Vree WJA, Vermeer MA, Weigh HA, Hanemaaijer R, van Hinsberg VWM. Cooperative effect of tumor necrosis factor-α and angiogenic growth factors on the formation of tubular structures of human microvascular endothelial cells in a three-dimensional fibrin matrix. Role of pericellular urokinase activity. J Cell Biol 1996; 132: 1177-88.
    CrossrefPubMedGoogle Scholar
  • 15 Emeis JJ, van den Eijnden-Schrauwen Y, Kooistra T. Tissue-type plasminogen activator and the vessel wall: synthesis, storage and secretion. In: Vascular control of haemostasis. Van Hinsbergh VWM. (ed) Victoria, Australia: Gordon and Breach Science Publishers; 1996: 187-206.
    Google Scholar
  • 16 Kounnas MZ, Henkin J, Argraves WS, Strickland DK. Low density lipoprotein receptor-related protein/α2-macroglobulin receptor mediates cellular uptake of pro-urokinase. J Biol Chem 1993; 268: 21862-7.
    PubMedGoogle Scholar
  • 17 Orth K, Willnow T, Herz J, Gething MJ, Sambrook JF. Low density lipoprotein receptor-related protein is necessary for the internalization of both tissue-type plasminogen activator-inhibitor complexes and free tissue-type plasminogen activator. J Biol Chem 1994; 269: 21117-22.
    PubMedGoogle Scholar
  • 18 Kluft C. Constitutive synthesis of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1): conditions and therapeutic targets. Fibrinolysis 1994; 8 (Suppl. 02) 1-7.
    PubMedGoogle Scholar
  • 19 Aro J, Haapiainen R, Rasi V, Rannikko S, Alfthan O. The effect of parenteral estrogen versus orchiectomy on blood coagulation and fibrinolysis in prostatic cancer patients. Eur Urol 1990; 17: 161-5.
    CrossrefPubMedGoogle Scholar
  • 20 Blomback M, Hedlund PO, Sawe U. Changes in blood coagulation and fibrinolysis in patients on different treatment regimens for prostatic cancer. Predictors for cardiovascular complications? Thromb Res 1988; 49: 111-21.
    PubMedGoogle Scholar
  • 21 Gevers Leuven JA, Kluft C, Bertina RM, Hessel LW. Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems. J Lab Clin Med 1987; 109: 631-6.
    PubMedGoogle Scholar
  • 22 Gebara OC, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, Wilson PW, Levy D, Muller JE. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91: 1952-8.
    CrossrefPubMedGoogle Scholar
  • 23 Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78: 315-26.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Anderson RA, Ludlam CA, Wu FCW. Haemostatic effects of supraphysiological levels of testosterone in normal men. Thromb Haemost 1995; 74: 693-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Sporn LA, Marder VJ, Wagner DD. Differing polarity of the constitutive and regulated secretory pathways for von Willebrand factor in endothelial cells. J Cell Biol 1989; 108: 1283-9.
    CrossrefPubMedGoogle Scholar
  • 26 Stel HV, Sakariassen KS, de Groot PG, van Mourik JA, Sixma JJ. von Wille-brand factor in the vessel wall mediates platelet adherence. Blood 1985; 65: 85-90.
    PubMedGoogle Scholar
  • 27 Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO, Marder VJ. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci USA 1987; 84: 1955-9.
    CrossrefPubMedGoogle Scholar
  • 28 Silveira AM, Elgue G, Hamsten A, Blombäck M. von Willebrand factor in plas ma and urine of men with premature coronary artery disease. Thromb Haemost 1992; 67: 161-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Harrison RL, McKee PA. Estrogen stimulates von Willebrand factor production by cultured endothelial cells. Blood 1984; 63: 657-65.
    PubMedGoogle Scholar
  • 30 Kooistra T, Bosma PJ, Jespersen J, Kluft C. Studies on the mechanism of action of oral contraceptives with regard to fibrinolytic variables. Am J Obstet Gynecol 1990; 163: 404-13.
    CrossrefPubMedGoogle Scholar
  • 31 Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex. Relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 1997; 96: 761-8.
    CrossrefPubMedGoogle Scholar
  • 32 Polderman KH, Stehouwer CDA, van Kamp GJ, Dekker GA, Verheugt FWA, Gooren LJG. Influence of sex hormones on plasma endothelin levels. Ann Intern Med 1993; 118: 429-32.
    CrossrefPubMedGoogle Scholar
  • 33 White MW, Zamudio S, Stevens T, Tyler R, Lindenfeld J, Leslie K, Moore LG. Estrogen, progesterone, and vascular reactivity: potential cellular mechanisms. Endocr Rev 1995; 16: 739-51.
    PubMedGoogle Scholar
  • 34 Webb D. Physiological role of the endothelin system in human cardiovascular and renal haemodynamics. Curr Opin Nephrol Hypertens 1997; 6: 69-73.
    CrossrefPubMedGoogle Scholar
  • 35 Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 1994; 91: 5212-6.
    CrossrefPubMedGoogle Scholar
  • 36 Mikkola T, Turunen P, Avela K, Orpana A, Viinikka L, Ylikorkala O. 17β-estradiol stimulates prostacyclin, but not endothelin-1, production in human vascular endothelial cells. J Clin Endocrinol Metab 1995; 80: 1832-6.
    PubMedGoogle Scholar
  • 37 Ferri C, Bellini C, Desideri G, Di Francesco L, Baldoncini R, Santucci A, De Mattia G. Plasma endothelin-1 levels in obese hypertensive and normotensive men. Diabetes 1995; 44: 431-6.
    CrossrefPubMedGoogle Scholar